COVID-19 Drug Discovery Assays

Reaction Biology understands the increasingly urgent need to address the COVID-19 situation with clinically approved therapeutic drugs. To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication.

Our COVID-19 therapeutic drug testing service is available for pharmaceutical companies and medical researchers worldwide. Get in touch with the business development manager assigned to your country today.

Our SARS-CoV-2 drug screening services include:

The SARS-CoV-2 Spike protein and ACE2 binding assay is used to measure the direct binding of potential therapeutics to the Spike protein receptor-binding domain or ACE2 to determine the kinetics of the interaction or to measure whether the test molecule(s) disrupt the Spike/ACE2 interaction.

We perform this assay at our Malvern, PA facility using surface plasmon resonance (SPR) technology. Our team uses state-of-the-art Biacore 8K units that ensure accurate and comprehensive results. The standard turnaround time is two weeks.

We offer compound screening assays targeting proteases that are essential for SARS-CoV-2 virus entry and replication. These target proteases include ACE2, TMPRSS2, Main Protease (Mpro), PLpro and more.

Our protease assay screening service comprises fluorescence-based activity assays for low and large-scale screening, and for off-target analysis via full protease panel screening.